- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03348761
rTMS Response Trajectories in Depression
Pre-treatment Biomarker for Clinical Response to Neuronavigation Repetitive Transcranial Magnetic Stimulation (rTMS) in the Acute Phase Treatment of Refractory Major Depressive Episode- Role of Intrinsic Functional Connectivity
Study Overview
Detailed Description
- Sampling Clinical participants will be recruited from the Transcranial Magnetic Stimulation Day Care Centre of Tai Po Hospital based in the New Territories East Service Cluster under the public sector. Written informed consent will be obtained from all participants according to the Declaration of Helsinki. Each subject will be paid HKD$800 to subsidize their travel.
Pre-treatment assessment
- Baseline clinical assessment (one week before the first TMS session) Apart from collecting the basic demographic profile of the research participant (age, education level, gender), the research psychiatrist will administer MADRS, DSM-IV, SCID-I/II to ascertain current/ lifetime Axis I and II psychiatric diagnosis, age at onset of MDD and number of major depressive episodes, number of failed antidepressants and clinical global impression scale (CGI) of the current episode. The psychiatrist will also review the past and current significant medical history from the Hospital Authority's Clinical Management System supplemented by participant's self-report. Participant will complete Beck Depression Inventory that has been validated in local Chinese dialect. Handedness is assessed with the Edinburgh Handedness Inventory.
- Pre-treatment MRI of Brain Pre-treatment MRI will be acquired up to two weeks before treatment on a 3.0 T Philips Achieva Medical Scanner with an eight-channel SENSE head coil (Philips Healthcare, The Netherlands) at the Prince of Wales Hospital, New Territories East Service Cluster of Hospital Authority of Hong Kong. The first scan is a high-resolution T1-weighted structural scan covering the whole brain acquired with the following parameters: repetition time = 7.54 ms, echo time = 3.53 ms, flip angle = 8⁰, 1.1 x 1.1 x 0.6 mm voxels, number of slices = 285, slice orientation = sagittal, slice thickness = 1.2 mm, Field of View = 250 mm3, and matrix size = 240 x 240. This scan will be used to register with the resting-state fMRI data, and for segmentation into grey matter, white matter and cerebrospinal fluid, and normalization to template space. Following the T1-weighted sequence, a 12-minute resting-state fMRI scan will be collected with the following protocol: repetition time = 2050ms, echo time = 25ms, flip angle = 90⁰, 3.2 mm3 voxels, slice thickness = 3.2 mm, Field of View = 205 mm², and matrix size = 64 x 64. Participants will be instructed to look at a fixation cross during the scan session.
- TMS device, stimulation target localization and stimulation parameters MagVita X100 will be used to deliver intermittent theta burst stimulation (iTBS) to left DLPFC in the Transcranial Magnetic Stimulation Day Care Centre of Tai Po Hospital. The treatment facility is fully funded and operated by the Hospital Authority as part of the drug-resistant protocol accessible to all patients receiving specialist psychiatric service in the public sector and was established since 2021. All treatment sessions are delivered by qualified operators (psychiatrists or nurses) as part of the core clinical service. The treatment protocol adopts F3 beam target with MagVita X100 following the manufacturer's guide that utilizes a formulaic estimation of F3 location system. The US-FDA approved 3-minute intermittent theta-burst protocol (i-TBS) 18 comprises of 18 cycles of 10 bursts. Each burst is triplet of pulses discharged at 50 hz and the burst frequency is 5Hz. Between two cycles of bursts is 8-second inter-train rest. The device output is set at 120% above the resting motor threshold determined on the observable motor excitability on M1 motor cortex corresponding to the right-hand abductor pollicis brevis (at least 5 out of 10 trials reaching 50 microvolt read from MEG in response to single pulse TMS). The resting motor threshold is determined only once every week. The full course includes 20 daily sessions over four weeks.
- Follow-up assessments are scheduled at the end of week 2, week 4, week 6, week 8, and week 12 to delineate the trajectory of depressive symptoms over a course of 12 weeks. Primary outcome measures are the scores on MADRS and CGI at the end of week 4 and week 12. Secondary outcome measure is score on BDI at the end of week 4 and week 12. Patients are classified as short-term responders where clinical response is defined as CGI= 2 and >/=50% reduction of MADRS score from baseline at the end of week 4. For those who fulfill clinical response where CGI= 2 and there is >/=50% reduction of MADRS score from baseline at the end of week 12 are classified as long-term responders. Patients are classified as short-term remitters where clinical remission is defined as CGI= 1 and MADRS score<7, respectively at the end of week 4. For those who fulfill clinical remission where CGI= 1 and MADRS score is <7 at the end of week 12 are classified as long-term remitters.
- Serum BDNF level would be evaluated at baseline (within 2 weeks before treatment), at the end of week 2, week 4 and week 12 as a neurochemical biomarker of neuroplastic response. Blood samples will be collected in anticoagulant-free tubes and kept at room temperature for 1 hour before further blood sample processing. The serum collected will be used for serum marker assay. The blood samples collected in anticoagulant-free tubes would be centrifuged at 3500g, at 4°C for 10 minutes within 3 hours of blood collection to obtain serum and stored at -70°C until assay. Commercial ELISA kit will be used to assay the levels of BDNF. Measurement will be performed accordingly to manufacturer's instructions. Samples and standards will be run in duplicate and BDNF concentrations will be calculated using the standard curve. BDNF (Val66Met) will be genotyped to explore its relationship with neuroplastic change and clinical response in this study. In brief, DNA will be extracted by commercial DNA extraction kit from blood samples according to manufacturer's instruction. It will then be genotyped by Taqman genotyping assay.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: The Department of Psychiatry
- Phone Number: 852-2607-6027
- Email: psychiatry@cuhk.edu.hk
Study Contact Backup
- Name: Helene J Hopman
- Phone Number: 852-5597-1622
- Email: hjhopman@link.cuhk.edu.hk
Study Locations
-
-
-
Hong Kong, Hong Kong, 852
- Recruiting
- Department of Psychiatry, CUHK
-
Contact:
- Wing Sze Ho, M.Sc
- Phone Number: 852-6309-3272
- Email: stephy0306@hotmail.com
-
Contact:
- Helene J Hopman, PhD
- Phone Number: 852-5597-1622
- Email: hjhopman@cuhk.edu.hk
-
Principal Investigator:
- Sau Man S Chan
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- right-handed
- meet the Diagnostic and Statistical Manual of Mental Disorder, Fourth Edition (DSM-IV) criteria for major depressive disorder
- at least moderate episode or with a score of >20 on Montgomery-asberg Depression Rating Scale (MADRS) and >18 on Hamilton Depression Rating Scale(HDRS) 17-item;
- has failed to respond adequately to at least one full course (>6 weeks) of antidepressant medication or medication intolerant.
Exclusion Criteria:
- significant head trauma
- active abuse of alcohol or illegal substances
- current psychotic symptoms
- suicide ideation/recent suicide attempts
- other DSM-IV Axis I and II psychiatric diagnosis
- neurological disorders and contraindications to fMRI (e.g. pace makers, metal implants, pregnancy) or rTMS, or having undergone electroconvulsive therapy in the preceding year.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: rTMS Group
Phase I: A Magstim Super-Rapid device with a 70-mm figure-of-eight double air film coil (Magstim Ltd, UK) and Brainsight neuronavigation (Rogue Resolutions Ltd, Canada) are used. Stimulation parameters: 10 Hz, 120% resting motor threshold, 30 trains of 5 seconds with 25 seconds rest, 3000 pulses per day delivered 5 days per week (total: 60000 pulses). Phase II: MagVita X100 (FDA approved device) will be used to deliver intermittent theta burst stimulation (iTBS) to left DLPFC, comprising of 18 cycles of 10 bursts. Each burst is triplet of pulses discharged at 50 hz and the burst frequency is 5Hz. Between two cycles of bursts is 8-second inter-train rest. The device output is set at 120% above the resting motor threshold |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Montgomery-Ashberg Depression Rating Scale
Time Frame: Percentage change baseline versus week 4
|
Questionnaire used to measure the severity of depressive symptoms and treatment response in patients with mood disorders consisting of 10 items.
The score range is 0-60 and higher score indicates more severe depression.
|
Percentage change baseline versus week 4
|
Montgomery-Ashberg Depression Rating Scale
Time Frame: Percentage change baseline versus week 6
|
Questionnaire used to measure the severity of depressive symptoms and treatment response in patients with mood disorders consisting of 10 items.
The score range is 0-60 and higher score indicates more severe depression.
|
Percentage change baseline versus week 6
|
Montgomery-Ashberg Depression Rating Scale
Time Frame: Percentage change baseline versus week 8
|
Questionnaire used to measure the severity of depressive symptoms and treatment response in patients with mood disorders consisting of 10 items.
The score range is 0-60 and higher score indicates more severe depression.
|
Percentage change baseline versus week 8
|
Montgomery-Ashberg Depression Rating Scale
Time Frame: Percentage change baseline versus week 12
|
Questionnaire used to measure the severity of depressive symptoms and treatment response in patients with mood disorders consisting of 10 items.
The score range is 0-60 and higher score indicates more severe depression.
|
Percentage change baseline versus week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical Global Impression Scale
Time Frame: Percentage change baseline versus week 4
|
A 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis.
Score of 2 indicates significant clinical response while score of 1 indicates clinical remission.
|
Percentage change baseline versus week 4
|
Clinical Global Impression Scale
Time Frame: Percentage change baseline versus week 6
|
A 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis.
Score of 2 indicates significant clinical response while score of 1 indicates clinical remission.
|
Percentage change baseline versus week 6
|
Clinical Global Impression Scale
Time Frame: Percentage change baseline versus week 8
|
A 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis.
Score of 2 indicates significant clinical response while score of 1 indicates clinical remission.
|
Percentage change baseline versus week 8
|
Clinical Global Impression Scale
Time Frame: Percentage change baseline versus week 12
|
A 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis.
Score of 2 indicates significant clinical response while score of 1 indicates clinical remission.
|
Percentage change baseline versus week 12
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Sau Man S Chan, Chinese University of Hong Kong
Publications and helpful links
General Publications
- Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979 Apr;134:382-9. doi: 10.1192/bjp.134.4.382.
- HAMILTON M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960 Feb;23(1):56-62. doi: 10.1136/jnnp.23.1.56. No abstract available.
- Fox MD, Buckner RL, White MP, Greicius MD, Pascual-Leone A. Efficacy of transcranial magnetic stimulation targets for depression is related to intrinsic functional connectivity with the subgenual cingulate. Biol Psychiatry. 2012 Oct 1;72(7):595-603. doi: 10.1016/j.biopsych.2012.04.028. Epub 2012 Jun 1.
- Whitfield-Gabrieli S, Nieto-Castanon A. Conn: a functional connectivity toolbox for correlated and anticorrelated brain networks. Brain Connect. 2012;2(3):125-41. doi: 10.1089/brain.2012.0073. Epub 2012 Jul 19.
- Behzadi Y, Restom K, Liau J, Liu TT. A component based noise correction method (CompCor) for BOLD and perfusion based fMRI. Neuroimage. 2007 Aug 1;37(1):90-101. doi: 10.1016/j.neuroimage.2007.04.042. Epub 2007 May 3.
- So E, Kam I, Leung CM, Chung D, Liu Z, Fong S. The Chinese-Bilingual SCID-I/P Project: stage 1- reliability for mood disorders and schizophrenia. East Asian Archives of Psychiatry 2003; 13: 7-18.
- Wong HM, Chow LY. Borderline personality disorder subscale (Chinese version) of the structured clinical interview for DSM-IV axis II personality disorders: a validation study in Cantonese-speaking Hong Kong Chinese. East Asian Arch Psychiatry. 2011 Jun;21(2):52-7.
- Ballenger JC. Clinical guidelines for establishing remission in patients with depression and anxiety. J Clin Psychiatry. 1999;60 Suppl 22:29-34.
- Beck A, Steer R, Brown G. RCMAR Measurement Tools Beck Depression Inventory - 2nd Edition (BDI-II). The Psychological Corporation, San Antonio 1996.
- Wu PC, Chang L. Psychometric Properties of the Chinese Version of the Beck Depression Inventory-II Using the Rasch Model. Measurement & Evaluation in Counseling & Development 2008; 41:13-31.
- Trull TJ, Geary DC. Comparison of the big-five factor structure across samples of Chinese and American adults. J Pers Assess. 1997 Oct;69(2):324-41. doi: 10.1207/s15327752jpa6902_6.
- Lo CS, Ho SM, Hollon SD. The effects of rumination and negative cognitive styles on depression: a mediation analysis. Behav Res Ther. 2008 Apr;46(4):487-95. doi: 10.1016/j.brat.2008.01.013. Epub 2008 Jan 30.
- Robinson LA, Alloy LB. Negative cognitive styles and stress-reactive rumination interact to predict depression: a prospective study. Cognitive therapy and research 2003; 27: 275-292.
- Murphy K, Fox MD. Towards a consensus regarding global signal regression for resting state functional connectivity MRI. Neuroimage. 2017 Jul 1;154:169-173. doi: 10.1016/j.neuroimage.2016.11.052. Epub 2016 Nov 22.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CRE-2014.041
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Lawson Health Research InstituteTerminated
Clinical Trials on rTMS group
-
Institut GuttmannInstituto de Salud Carlos IIICompleted
-
Beni-Suef UniversityCairo UniversityCompleted
-
University of Sao Paulo General HospitalUnknownMild Cognitive ImpairmentBrazil
-
Beijing Tiantan HospitalNot yet recruitingIschemic Stroke | Post-stroke Cognitive Impairment
-
Cairo UniversityKasr El Aini HospitalCompletedStroke, CardiovascularEgypt
-
Shanghai Mental Health CenterYunnan Institute For Drug Abuse; Wuxi Mental Health Center, Jiangsu Provence... and other collaboratorsCompletedMethamphetamine-dependenceChina
-
Assistance Publique - Hôpitaux de ParisNot yet recruiting
-
University of FloridaNational Institute of Neurological Disorders and Stroke (NINDS)CompletedDystonia | TremorUnited States
-
IRCCS Centro Neurolesi "Bonino-Pulejo"Recruiting
-
Aalborg UniversityCompleted